Russia's sovereign wealth fund and its partner Chemrar will supply the Covid-19 drug Avifavir to 17 additional countries, the fund said in a statement.
Avifavir gained approval from the Russian health ministry in May and is based on Favipiravir, which was developed in Japan and is widely used there as the basis for viral treatments, according to Reuters.
Avifavir has already been delivered to Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan.
It will now be sent to Argentina, Bulgaria, Brazil, Chile, Colombia, Ecuador, El Salvador, Honduras, Kuwait, Panama, Paraguay, Saudi Arabia, Serbia, Slovakia, South Africa, the UAE and Uruguay, the the Russian Direct Investment Fund said.
